Previous 10 | Next 10 |
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its ...
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D. , founder and chief executive officer of Crinetics, will present at the 42 nd Annual J.P. Morgan Healthcare Conference, which is taking place in San ...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-30 20:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is Complete (N=36), and Topline Re...
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that...
2023-11-30 13:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-28 15:36:20 ET Summary Today, we take a deeper look at Crinetics Pharmaceuticals, Inc., which has seen a significant increase in its stock price in recent months. The company's primary drug candidate, paltusotine, looks like it could become a best of breed treatment for th...
2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6 th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35 th Annual Healthcare ...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy,...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more t...
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of Analog Devices, Inc. (NASDAQ:ADI) rose s...